Keywords: ACT; artemisinin-based combination therapy; ANOVA; analysis of variance; CI; confidence interval; CYP2D6; cytochrome P450 2D6; DHAP; dihydroartemisinin-piperaquine; G6PD; glucose-6-phosphate dehydrogenase; HR; hazards ratio; IQR; interquartile ratio; MD;